Serous Cystadenoma of the Pancreas Showing Uptake on 68Ga PSMA PET/CT

Chan, Mico; Schembri, Geoffrey; Hsiao, Edward

doi:10.1097/rlu.0000000000001423

Cited by 20 publications

(8 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 The case presented here demonstrates that 68 Ga-PSMA-11 PET/CT can detect head and neck squamous cell carcinoma. Our case further highlights that PSMA is not as specific as originally believed and uptake can be found in many other types of neoplasms [5][6][7][8][9][10][11][12][13][14][15] as well as benign pathologies. [16][17][18][19]…”

mentioning

confidence: 62%

Incidental Detection of Head and Neck Squamous Cell Carcinoma on 68Ga-PSMA-11 PET/CT

Lawhn-Heath

Flavell²,

Glastonbury³

et al. 2017

Clinical Nuclear Medicine

View full text Add to dashboard Cite

We present a case of an incidentally detected squamous cell carcinoma of the oropharynx on 68 Ga-PSMA-11 PET. A 71-year-old man's condition was diagnosed as prostate carcinoma after a year of rising serum prostate-specific antigen. The staging 68 Ga-PSMA PET/CT demonstrated focal radiotracer uptake in the prostate corresponding to his known primary prostate cancer. However, a PSMA-avid 3.4-cm mass was incidentally found in the right tongue base that was biopsied, confirming squamous cell carcinoma.

show abstract

mentioning

confidence: 62%

Incidental Detection of Head and Neck Squamous Cell Carcinoma on 68Ga-PSMA-11 PET/CT

Lawhn-Heath

Flavell²,

Glastonbury³

et al. 2017

Clinical Nuclear Medicine

View full text Add to dashboard Cite

show abstract

“…The rapidly expanding role of 68 Ga-labeled PSMA PET/CT in prostate cancer needs careful evaluation as its specificity is limited by some false-positive findings as enumerated in the present article [ Table 1 ]. [ 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 ] Knowledge of these limitations can decrease the potential diagnostic pitfalls and increase the confidence of interpreting physicians.…”

Section: Benign Diseasesmentioning

confidence: 99%

Nonspecific uptake of ⁶⁸Ga-prostate-specific membrane antigen in diseases other than prostate malignancy on positron emission tomography/computed tomography imaging: A pictorial assay and review of literature

et al. 2018

View full text Add to dashboard Cite

68Ga-labeled prostate-specific membrane antigen (PSMA) ligand positron emission tomography/computed tomography imaging (PET/CT) is a rapidly evolving imaging modality for prostate cancer. Many studies have proved its superiority in staging, restaging, and detecting the recurrent prostate cancer. However, case reports describing the incidental tracer uptake in benign and nonprostatic malignancies are also reported in the literature, thus questioning the specificity of the tracer. This pictorial assay illustrates the nonspecific tracer uptake encountered during PSMA PET/CT imaging, knowledge of which can increase the confidence of interpreting physicians and may also open a new path for peptide receptor radionuclide therapy in nonprostatic malignancies.

show abstract

“…13 PSMA ligands with nonspecific binding properties have a high possibility of off-target binding, which may be related to false-positive cases in PSMA-positron emission tomography (PET) clinical studies. [14][15][16][17][18] In this regard, there is still a need for more PSMA-specific ligands with less off-target binding.…”

Section: Introductionmentioning

confidence: 99%

¹⁸F‐labeled 1,2,3‐triazole‐linked Glu‐urea‐Lys‐based PSMA ligands have good pharmacokinetic properties for positron emission tomography imaging of prostate cancer

et al. 2020

View full text Add to dashboard Cite

Background: Prostate-specific membrane antigen (PSMA) is increasingly recognized as an excellent target for prostate cancer imaging and therapy. Finding compounds with a high target-to-nontarget ratio are an important challenge in the development of positron emission tomography (PET) imaging agents. In this study, we attempted to find a suitable compound from a simply-synthesized compound library. Method: 18 F-labeling was achieved in a two-step synthesis consisting of [ 18 F]fluorination of azido sulfonates followed by copper(I)-catalyzed click ligation. In vitro binding experiment and in vivo studies were carried out using isogenic PSMA+ PC3-PIP and PSMA− PC3-flu cells and 22RV1 cells. [ 125 I]MIP-1095 was used to measure the binding affinities of compounds through a competitive binding assay, and [ 18 F] DCFPyL was used for a comparative assessment of compounds. Radiation dosimetry data were obtained using OLINDA/EXM software. Results: Nine novel PSMA ligands were synthesized by the combination of three azido compounds and three terminal acetylene-containing Glu-urea-Lys compounds. Among them, compound 6f having a pyridine moiety showed a high binding affinity of 6.51 ± 0.19 nM (K i). 18 F-labeled compounds were obtained at moderate yields within 70 to 75 minutes (including high-performance liquid chromatography purification). Compound [ 18 F]6c had the lowest log P of −2.693. MicroPET/computed tomography (CT) images were acquired from 22RV1 cell xenograft mice after injecting [ 18 F]6c, [ 18 F]6f, and [ 18 F]6i. Additional microPET/CT experiments of [ 18 F]6c and [ 18 F]6f were performed using PSMA+ PC3-PIP and PSMA− PC3-flu cell-bearing mice. [ 18 F]6c was selected for further studies because it was found to have high uptake in tumors and rapid renal clearance, resulting in great tumor-to-nontumor ratios and distinct tumor images with very low background activity. Human dosimetry estimation of [ 18 F]6c using OLINDA/EXM software was calculated, resulting in an effective dose of 4.35 × 10 −3 mSv/MBq. Conclusions: [ 18 F]6c showed significant tumor uptake, a high tumor-to-nontumor ratio, and good radiation dosimetry results, suggesting further development as a potential diagnostic PET agent for prostate cancer.

show abstract

Serous Cystadenoma of the Pancreas Showing Uptake on 68Ga PSMA PET/CT

Cited by 20 publications

References 9 publications

Incidental Detection of Head and Neck Squamous Cell Carcinoma on 68Ga-PSMA-11 PET/CT

Incidental Detection of Head and Neck Squamous Cell Carcinoma on 68Ga-PSMA-11 PET/CT

Nonspecific uptake of ⁶⁸Ga-prostate-specific membrane antigen in diseases other than prostate malignancy on positron emission tomography/computed tomography imaging: A pictorial assay and review of literature

¹⁸F‐labeled 1,2,3‐triazole‐linked Glu‐urea‐Lys‐based PSMA ligands have good pharmacokinetic properties for positron emission tomography imaging of prostate cancer

Contact Info

Product

Resources

About

Serous Cystadenoma of the Pancreas Showing Uptake on 68Ga PSMA PET/CT

Cited by 20 publications

References 9 publications

Incidental Detection of Head and Neck Squamous Cell Carcinoma on 68Ga-PSMA-11 PET/CT

Incidental Detection of Head and Neck Squamous Cell Carcinoma on 68Ga-PSMA-11 PET/CT

Nonspecific uptake of 68Ga-prostate-specific membrane antigen in diseases other than prostate malignancy on positron emission tomography/computed tomography imaging: A pictorial assay and review of literature

18F‐labeled 1,2,3‐triazole‐linked Glu‐urea‐Lys‐based PSMA ligands have good pharmacokinetic properties for positron emission tomography imaging of prostate cancer

Contact Info

Product

Resources

About

Nonspecific uptake of ⁶⁸Ga-prostate-specific membrane antigen in diseases other than prostate malignancy on positron emission tomography/computed tomography imaging: A pictorial assay and review of literature

¹⁸F‐labeled 1,2,3‐triazole‐linked Glu‐urea‐Lys‐based PSMA ligands have good pharmacokinetic properties for positron emission tomography imaging of prostate cancer